Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Prospective Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer (L1ST)

NCT05846594 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05846594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05846594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Prospective Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer (L1ST)
Lead sponsor
Hoffmann-La Roche
Phase
Not applicable
Overall status
Completed
Start date
September 14, 2023
Completion date
September 6, 2024
Enrollment
463 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastrointestinal cancer, metastatic lung cancer